How many stocks are there of Sesen Bio?
The current number of stocks of Sesen Bio is 10.03 M undefined.
Sesen Bio Stocks 2024
Sesen Bio Stocks
10.03 M
Ticker
SESN
ISIN
US8177631053
WKN
A2JL47
In 2024, Sesen Bio had 10.03 M outstanding stocks, a 0% change from the 10.03 M stocks in the previous year.
The Sesen Bio Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2028e | 10.03 |
| 2027e | 10.03 |
| 2026e | 10.03 |
| 2025e | 10.03 |
| 2024e | 10.03 |
| 2023e | 10.03 |
| 2022 | 10.03 |
| 2021 | 9.12 |
| 2020 | 5.91 |
| 2019 | 90.93 |
| 2018 | 61.77 |
| 2017 | 26.11 |
| 2016 | 21.73 |
| 2015 | 18.99 |
| 2014 | 14.64 |
| 2013 | 1.35 |
| 2012 | 1.64 |
| 2011 | 1.64 |
Sesen Bio shares outstanding US8177631053 · A2JL47
The number of shares was Sesen Bio in 2023 — This indicates how many shares 10.027 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Sesen Bio earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Sesen Bio's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Sesen Bio’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sesen Bio's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2011 | 1.64 M Aktien |
| 2012 | 1.64 M Aktien |
| 2013 | 1.35 M Aktien |
| 2014 | 14.64 M Aktien |
| 2015 | 18.99 M Aktien |
| 2016 | 21.73 M Aktien |
| 2017 | 26.11 M Aktien |
| 2018 | 61.77 M Aktien |
| 2019 | 90.93 M Aktien |
| 2020 | 5.91 M Aktien |
| 2021 | 9.12 M Aktien |
| 2022 | 10.03 M Aktien |
| 2023e | 10.03 M Aktien |
| 2024e | 10.03 M Aktien |
| 2025e | 10.03 M Aktien |
| 2026e | 10.03 M Aktien |
| 2027e | 10.03 M Aktien |
| 2028e | 10.03 M Aktien |
Sesen Bio Aktienanalyse
What does Sesen Bio do?
Sesen Bio Inc. is a biotechnology company focused on developing advanced therapeutics for the treatment of cancer and other challenging diseases. The company was founded in 2010 in Cambridge, Massachusetts, and has since expanded its research and development efforts to develop a range of therapies based on its innovative technologies and approaches. The goal of Sesen Bio is to develop groundbreaking drugs and therapies that are both safe and effective, helping patients successfully fight their illness. The company's focus is on unlocking new treatment possibilities through its proprietary platforms, including its antibody-drug conjugate (ADC) technology, on which all drug candidates are based. Sesen Bio has three main divisions: cancer treatment, therapy development, and partnership program. The cancer treatment division focuses on clinical trials and product marketing. This is where the first approved drug, Vicinium, is mentioned. Vicinium is an ADC consisting of a monoclonal antibody against prostate-specific membrane antigen (PSMA). It is indicated for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The therapy development division is involved in creating drug candidates and advancing their development through clinical trials. The partnership program allows Sesen Bio to license and commercialize its technologies and platforms by partnering with other biotechnology companies and pharmaceutical companies. The company has made significant progress in the development of therapeutics in recent years. The first approved drug, Vicinium, has propelled the company forward. The company is conducting clinical trials on other drug candidates to evaluate their efficacy and safety. Additionally, the company has a pipeline of new products in various stages of development, including NG-348, a novel ADC targeting the epidermal growth factor receptor (EGFR) that can be used in the treatment of solid tumors in various organs. Sesen Bio aims to further expand its innovative technologies in the field of cancer therapy and expand its offering of groundbreaking therapeutics. The company works closely with its partners and customers to develop customized treatment solutions and ensure high patient satisfaction. With its dedicated research and development department, well-established partnerships, and ability to make groundbreaking technologies widely available, Sesen Bio is on track to become a leading company in the field of cancer therapy. Overall, Sesen Bio is an innovative biotechnology company dedicated to developing therapeutics that improve the lives of patients with cancer and other serious diseases. Through its proprietary technologies and platforms, dedicated research and development departments, and well-established partnerships, the company has established itself as a key player in the field of cancer therapy. Sesen Bio is a company with a vision and a mission that permeate everything it does, namely saving and improving lives. Sesen Bio ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Sesen Bio's Shares Outstanding
Sesen Bio's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Sesen Bio’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Sesen Bio’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Sesen Bio’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Sesen Bio stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Sesen Bio are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Sesen Bio evolved in recent years?
The number of shares of Sesen Bio has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Sesen Bio as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Sesen Bio?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Sesen Bio pay?
Over the past 12 months, Sesen Bio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sesen Bio is expected to pay a dividend of 0 USD.
What is the dividend yield of Sesen Bio?
The current dividend yield of Sesen Bio is .
When does Sesen Bio pay dividends?
Sesen Bio pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Sesen Bio?
Sesen Bio paid dividends every year for the past 0 years.
What is the dividend of Sesen Bio?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Sesen Bio located?
Sesen Bio is assigned to the 'Health' sector.
Wann musste ich die Aktien von Sesen Bio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Sesen Bio from 8/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/2/2024.
When did Sesen Bio pay the last dividend?
The last dividend was paid out on 8/2/2024.
What was the dividend of Sesen Bio in the year 2023?
In the year 2023, Sesen Bio distributed 0 USD as dividends.
In which currency does Sesen Bio pay out the dividend?
The dividends of Sesen Bio are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Sesen Bio stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Sesen Bio
Our stock analysis for Sesen Bio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sesen Bio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
